Quarterly Result11 May 2026, 05:51 pm
Corona Remedies FY26: Revenue up 17.3%, PAT Growth of 33.4%
AI Summary
Corona Remedies Ltd announced its FY26 financial results, reporting a 17.3% YoY revenue growth and a 33.4% YoY PAT growth. The company's performance was driven by brand-building initiatives and operational efficiencies. Key highlights include a 20.2% YoY revenue growth in Q4FY26, strategic acquisition of WOKADINE, and portfolio expansion with relaunched brands. The company improved its market position to 27th rank in India. Management commentary highlights strategic focus on brand building, specialty segments, and portfolio expansion.
Key Highlights
- Revenue grew by 20.2% YoY in Q4FY26 and 17.3% in FY26.
- Q4FY26 PAT grew by 43.7% and FY26 PAT grew by 33.4%.
- Acquired WOKADINE, entering the ₹648 Cr Povidone Iodine market.
- Improved market position to 27th rank in India.
- Chronic therapies contributed ~72% of total revenue in FY26.